MEDICLIN AG
MED
ISIN DE0006595101 / Valor 1158721
MEDICLIN AG
UMushroom community rating:
About company
MEDICLIN AG is a healthcare provider based in Germany, specializing in a comprehensive range of medical services. The company operates across the healthcare spectrum, focusing on acute care, rehabilitation (post-acute care), and inpatient nursing care services. With a network of facilities throughout Germany, MEDICLIN is positioned to offer a continuum of care to patients, encompassing immediate medical treatment, recovery, and long-term care. This integrated approach ensures that patients receive tailored healthcare services designed to meet their individual needs, from initial diagnosis through to rehabilitation and beyond. MEDICLIN's commitment to offering professional medical services is central to its operations, aiming to provide high-quality care across its various healthcare domains.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (08.11.2025):
In Q4 2023, MEDICLIN AG’s latest financial results demonstrate a mix of robust operational performance and some bottom‐line challenges. The Group reported steady sales of €183.0 million with healthy EBITDA and EBIT figures, even as the result attributable to shareholders slid into negative territory. The company's cash flow remained stable and its net financial debt was reduced impressively, underpinning efforts to invest in long-term capacity and innovation.
Sales Performance
For Q4 2023, MEDICLIN AG generated €183.0 million in sales, maintaining consistent revenue levels across the quarter.
Operational Efficiency
The latest figures show EBITDA of €30.5 million at a margin of 16.7% and an EBIT of €18.1 million, reflecting improvements in operational efficiency within the Group.
Shareholder Earnings
Despite strong operating metrics, MEDICLIN AG reported a negative result attributable to shareholders of –€25.9 million, with earnings per share coming in at –€0.55, pointing to challenges in overall profitability.
Cash Flow and Debt Position
Cash flow from operating activities remained solid at €28.1 million (or €0.59 per share). Notably, the net financial debt dropped significantly, effectively reaching zero, which underscores an improved liquidity profile.
Investments and Capital Allocation
Capital expenditure increased to €12.8 million in Q4 2023, signaling continued investment in future growth and capacity expansion, even as the equity ratio edged slightly down to 22.3%.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
193 M
Market cap (USD)
4,105
Daily traded volume (Shares)
2.42 / 2.34
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
